ADC Therapeutics SA
ZYNLONTA
relapsed or refractory diffuse large B-cell lymphoma
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“we intend to conduct a pre-sBLA meeting in August and are preparing for a planned sBLA submission in the fourth quarter of 2026”